Filter
200
Text search:
non-endemic
countries
Featured
33
34
Language
Document type
61
55
45
14
14
5
3
1
1
1
Countries / Regions
18
10
6
5
5
5
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
46
35
16
10
5
3
1
Toolboxes
82
17
16
8
7
5
4
4
2
2
2
1
1
1
1
1
1
1
1
1
1
1
PLoS Negl Trop Dis 15(8): e0009697. Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses t
...
The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines
...
Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th
...
This document provides technical guidance on concepts, definitions, indicators, criteria, milestones and tools to assist leprosy programmes in their journey towards the goals of interruption of transmission and elimination of leprosy disease and through the post-elimination period. Importantly, it p
...
The present guidelines incorporate all these changes, leading to a substantial reconfiguration of therapeutic choices for both disease forms.
HAT is a serious, life-threatening disease and the efficacy of fexinidazole depends on swallowing the medicine after an appropriate intake of food as well as
...
PLOS Neglected Tropical Diseases 18(4): e0012111. https://doi.org/10.1371/journal.pntd.0012111
The Lancet Microbe Series Chagas Disease 2 Volume 5, Issue 10100946 October 2024
The Lancet Regional Health - Americas 2024;36: 100821 https://doi.org/10.1016/j.lana.2024.100821
Guidelines approved by the WHO Guidelines -Review Committee; second edition
Guidelines for the treatment of human African trypanosomiasis. Web Annex A. Commissioned by WHO Cochrane Response
The Plan subscribes to the goals and pillars of the WHO Global Technical Strategy against Malaria 2016-2030 (GTS), while presenting key elements to address the specific challenges of the Region.
The Manual for Parasitological Surveillance in Prevention of Reintroduction or Re-establishment of Malaria in Sri Lanka (2019) provides guidelines to health professionals on how to conduct effective malaria surveillance to prevent the reintroduction of the disease in Sri Lanka, which was certified m
...
Growing emergencies and displacements across the world demand increasingly complex interventions and responses. The World Health Organization (WHO) has developed Malaria control in emergencies: a field manual to provide technical guidance to help partners respond effectively to malaria in emergency
...
This document serves to provide interim guidance/ recommendations to carry out mpox surveillance activities mainly case investigation, contact tracing and isolation. For the development of this document WHO, UKHSA and CDC guidelines were referred to and adopted within the country context.
A GUIDE FOR HEALTH WORKERS AND AUTHORITIES IN NIGERIA
WHO recommendations on adolescent health: guidelines approved by the WHO Guidelines Review Committee
This document is meant to respond to the questions:
■ What health interventions should the adolescent receive and when should s/he receive it?
■ What health behaviours should the adolescent practise (or not practise)?
■ What health interventions should the adolescent receive and when should s/he receive it?
■ What health behaviours should the adolescent practise (or not practise)?
Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers, second edition: web annex A: protocol for evaluating minimum package of care of morbidity management and disability prevention for lymphoedema management in designated health facilit
...
As the world recovers from the shock of the COVID-19 pandemic and reflects on lessons learnt from failure of global public health systems to contain the global outbreak of SARS-CoV-2, new infectious disease threats, caused by movement of people globally, remain omnipresent, and repeated calls for mo
...
